title: A multivariate analysis of patients with brain tumors treated with ATN-RNA.
abstract: Glioblastoma multiforme (GBM) is the most common form of malignant glioma, characterized by genetic instability, intratumoral histopathological variability, and unpredictable clinical behavior. Malignant gliomas express preferentially a number of surface markers that may be exploited as therapeutic targets, such as tenascin-C, an extracellular matrix glycoprotein contributes to tumor cell adhesion, invasion, migration and proliferation. Disappointing results in the treatment of gliomas with surgery, radiation and chemotherapy have fuelled a search for new treatment modalities. Here we present the data for 46 patients suffering from brain tumor. They were resected and treated with dsRNA (ATN-RNA) complementary to the sequence of tenascin-C mRNA. MRI and CT follow up studies showed growth tumor delay or lack of its recurrence symptoms, due to inhibition of TN-C synthesis. A significant improvement in overall survival (OS) was observed without loosing of the quality of life (QOL) of patients. This novel therapy based on RNA interference shows a big therapeutical potential. To our knowledge intervention with RNAi (iRNAi) is the first protocol of application of RNAi in human disease treatment.
authors.affiliation: Institute of Bioorganic Chemistry of the Polish Academy of Sciences, 12 Noskowskiego St., 61-704 Poznań, Poland.
authors.forename: Eliza
authors.initials: E
authors.lastname: Wyszko
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Rolle
authors.forename: Stanislaw
authors.initials: S
authors.lastname: Nowak
authors.forename: Ryszard
authors.initials: R
authors.lastname: Zukiel
authors.forename: Monika
authors.initials: M
authors.lastname: Nowak
authors.forename: Rafał
authors.initials: R
authors.lastname: Piestrzeniewicz
authors.forename: Iwona
authors.initials: I
authors.lastname: Gawrońska
authors.forename: Mirosława Z
authors.initials: MZ
authors.lastname: Barciszewska
authors.forename: Jan
authors.initials: J
authors.lastname: Barciszewski
mesh_terms: D000328:Adult; D000368:Aged; D001483:Base Sequence; D001932:Brain Neoplasms / Q000503:physiopathology / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D005909:Glioblastoma / Q000503:physiopathology / Q000628:therapy; D005910:Glioma / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local; D011788:Quality of Life; D034622:RNA Interference; D012330:RNA, Double-Stranded / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000378:metabolism; D015996:Survival Rate; D019063:Tenascin / Q000235:genetics / Q000378:metabolism*; D014057:Tomography, X-Ray Computed; D055815:Young Adult
chemical_list: D012330:RNA, Double-Stranded; D012333:RNA, Messenger; D019063:Tenascin